Oestrogen receptor gene overexpression – Diagnostics – Overview of Information and Clinical Research

Oestrogen receptor gene overexpression is a condition where the body produces too much of the protein that responds to estrogen hormones, most commonly seen in certain cancers, particularly breast cancer. Understanding how doctors identify this condition is essential for patients and their families, as early and accurate diagnosis can significantly influence treatment decisions and outcomes.

Introduction: Who Should Undergo Diagnostics

Diagnostic testing for oestrogen receptor gene overexpression is primarily important for people who have been diagnosed with certain types of cancer, especially breast cancer. Most breast cancers—approximately 70 to 75 percent—express estrogen receptors, meaning they grow in response to estrogen hormones.^[1]^[2] When the estrogen receptor gene is overexpressed, cancer cells produce more of these receptors than normal, making the tumor especially responsive to estrogen.

Women who have been newly diagnosed with breast cancer should undergo testing to determine whether their tumor is estrogen receptor-positive. This information helps doctors understand how the cancer might behave and which treatments are most likely to work. The test is typically performed on a tissue sample taken during a biopsy, which is a procedure where a small piece of the tumor is removed for examination.^[3] Testing is also advisable when cancer recurs or spreads to other parts of the body, as the receptor status can sometimes change over time.

People with a family history of breast or ovarian cancer may also benefit from genetic counseling and testing, though this is different from testing for receptor overexpression in existing tumors. Additionally, patients who develop resistance to hormone-based cancer treatments may need repeat testing to see if mutations have developed in the estrogen receptor gene itself, which can affect how well treatments work.^[4]^[6]

⚠️ Important

Not all breast cancers are estrogen receptor-positive. About 25 to 30 percent of breast cancers do not have these receptors and are called estrogen receptor-negative. These cancers require different treatment approaches and do not respond to hormone-based therapies. This is why accurate diagnostic testing is so critical for treatment planning.

Diagnostic Methods

Tissue Biopsy and Immunohistochemistry

The most common method for diagnosing oestrogen receptor gene overexpression is through tissue biopsy followed by a laboratory technique called immunohistochemistry, or IHC for short. During a biopsy, a doctor removes a small sample of the suspicious tissue, usually from a breast lump or tumor. This can be done using a needle or through a small surgical procedure. The tissue sample is then sent to a laboratory where specially trained scientists examine it under a microscope.^[2]

Immunohistochemistry works by using special antibodies that bind to estrogen receptors in the tissue sample. These antibodies are tagged with a dye or marker that becomes visible under the microscope. If estrogen receptors are present in large numbers—meaning there is overexpression—the tissue will show strong staining in the areas where cancer cells are located. Laboratory professionals count how many cancer cells show this positive staining to determine the receptor status. Generally, if more than one percent of cancer cells test positive for estrogen receptors, the tumor is classified as estrogen receptor-positive.^[3]

This testing also usually includes checking for progesterone receptors, another hormone receptor that often appears alongside estrogen receptors. The combination of results helps doctors understand the tumor’s characteristics more completely and plan the most effective treatment strategy.

Blood-Based Biomarker Testing

While tissue biopsy remains the gold standard for diagnosis, researchers are developing blood-based tests that can detect signs of estrogen receptor activity or mutations. These tests look for specific proteins or genetic material that indicate the presence of estrogen receptor overexpression or mutations in the estrogen receptor gene. Blood tests are less invasive than biopsies and can be repeated more easily to monitor changes over time.^[4]

Blood-based testing is particularly useful for patients with metastatic breast cancer—cancer that has spread to other parts of the body—where obtaining new tissue samples may be difficult or risky. These tests can help identify whether mutations have developed in the estrogen receptor gene that might make standard hormone treatments less effective. However, blood-based tests are typically used alongside, not instead of, tissue-based testing.

Genetic Sequencing for Mutations

In some cases, especially when cancer becomes resistant to treatment, doctors may order genetic sequencing of the estrogen receptor gene itself. This advanced testing looks for specific mutations within the gene that controls estrogen receptor production. Research has shown that certain mutations, particularly those affecting amino acids at positions 536, 537, and 538 of the receptor protein, are common in cancers that have stopped responding to hormone therapy.^[4]^[6]

These mutations can cause the estrogen receptor to become constantly active even without estrogen present, allowing cancer cells to grow despite treatment. The most frequently found mutations are called Y537S and D538G, which together account for a significant portion of treatment-resistant cases. Identifying these specific mutations can help doctors choose alternative treatments or enroll patients in clinical trials testing new therapies designed to overcome this resistance.

Gene Expression Profiling

Some patients may undergo gene expression profiling, a sophisticated test that examines the activity levels of multiple genes at once, including the estrogen receptor gene. These tests, sometimes called genomic tests or multi-gene panels, can provide information about how aggressive a cancer is likely to be and whether certain treatments will be beneficial. They analyze patterns of gene activity to predict cancer behavior and treatment response.^[7]

Gene expression tests look at groups of estrogen-responsive genes—genes that are turned on or off by estrogen signaling—to understand how actively the estrogen receptor pathway is functioning in a particular tumor. High expression of estrogen-responsive genes indicates that the tumor is highly dependent on estrogen signaling, which can influence treatment recommendations. These tests are sometimes used to help decide whether chemotherapy is needed in addition to hormone therapy.

Diagnostics for Clinical Trial Qualification

When patients are being considered for enrollment in clinical trials, more detailed and standardized diagnostic testing may be required. Clinical trials are research studies that test new treatments or combinations of treatments, and they often have specific requirements about which patients can participate based on their disease characteristics.

For trials testing new hormone therapies or drugs that target estrogen receptor-positive cancers, patients typically need documented proof of estrogen receptor overexpression through immunohistochemistry testing. The trial protocol will specify a minimum percentage of cancer cells that must test positive for estrogen receptors, commonly requiring at least one percent or sometimes higher thresholds like 10 percent positive cells.^[3]

Trials focused on treatment-resistant breast cancer often require testing for specific mutations in the estrogen receptor gene, particularly the common Y537S and D538G mutations. This testing may need to be performed using specific approved methods or in certified laboratories to ensure consistency and accuracy across all trial participants. Some trials may require both tissue-based and blood-based testing to confirm mutation status.^[4]^[6]

Additional tests required for clinical trial qualification might include measuring the levels of specific proteins or other biomarkers related to estrogen signaling. For example, trials might measure Ki-67, a protein that indicates how fast cancer cells are dividing, or check for expression of other genes that interact with the estrogen receptor pathway. These measurements help researchers ensure that trial participants have similar disease characteristics, making the study results more reliable and meaningful.

Some trials testing drugs designed to work specifically on mutant estrogen receptors require molecular characterization using next-generation sequencing, an advanced genetic testing method that can identify multiple mutations simultaneously. This comprehensive genetic analysis provides detailed information about all changes in the estrogen receptor gene and other cancer-related genes, helping researchers understand exactly which genetic alterations are driving cancer growth in each patient.^[6]

⚠️ Important

Clinical trials often provide access to cutting-edge treatments not yet available to the general public. If you have been diagnosed with estrogen receptor-positive cancer, especially if your cancer has not responded well to standard treatments, ask your doctor whether any clinical trials might be appropriate for you. The diagnostic tests required for trial enrollment are typically provided at no cost as part of the study.

Imaging studies may also be required for clinical trial qualification, though these assess the extent of disease rather than estrogen receptor status directly. Common imaging tests include CT scans, MRI scans, PET scans, and bone scans. These help determine whether cancer has spread and measure the size and location of tumors, information that trials need to assess whether treatments are working. Blood tests measuring overall health, including tests of liver and kidney function, blood cell counts, and heart function, are standard requirements to ensure patients can safely tolerate experimental treatments.

The timing of diagnostic tests matters for clinical trial enrollment. Some trials require that testing be performed within a certain timeframe before enrollment, such as within the past six months or three months. This ensures that the test results accurately reflect the patient’s current disease status, as cancer characteristics can change over time, particularly in patients who have received multiple prior treatments.

Prognosis and Survival Rate

Prognosis

The prognosis for patients with oestrogen receptor gene overexpression varies considerably depending on several factors. Generally, estrogen receptor-positive breast cancers tend to grow more slowly than estrogen receptor-negative cancers, which often translates to a better long-term outlook. However, the degree of estrogen receptor overexpression, the presence of other receptor types, the stage of cancer at diagnosis, and whether mutations develop over time all influence how the disease progresses.^[2]^[3]

Patients whose tumors show high levels of estrogen receptor expression typically respond well to hormone-based therapies, which work by blocking estrogen’s effects or reducing estrogen production in the body. These treatments can be highly effective at controlling cancer growth and preventing recurrence for many years. However, approximately 20 to 40 percent of patients with early-stage estrogen receptor-positive breast cancer eventually experience recurrence despite treatment.^[7]

The development of mutations in the estrogen receptor gene significantly worsens prognosis. These mutations, which are uncommon in newly diagnosed cancers but found in a substantial proportion of metastatic cases, allow cancer cells to grow without needing estrogen and make standard hormone therapies less effective. Patients whose cancers develop these mutations, particularly the common Y537S and D538G mutations, often experience disease progression despite ongoing hormone treatment and may require alternative therapeutic approaches.^[4]^[6]

Factors that improve prognosis include earlier stage at diagnosis, absence of spread to lymph nodes, smaller tumor size, lower tumor grade, and good response to initial treatments. Women diagnosed with estrogen receptor-positive breast cancer at early stages who receive appropriate hormone therapy often have excellent long-term outcomes. Conversely, factors associated with poorer prognosis include the presence of mutations, development of treatment resistance, high proliferation rates indicated by markers like Ki-67, and spread to distant organs.^[7]

Survival Rate

Survival rates for estrogen receptor-positive breast cancer depend heavily on the stage at diagnosis and treatment response. For patients with localized disease caught early, five-year survival rates are very high, often exceeding 90 percent with appropriate treatment including surgery and hormone therapy. When cancer has spread to nearby lymph nodes but not distant sites, five-year survival rates remain favorable but somewhat lower, typically ranging from 80 to 90 percent depending on various factors.^[2]

Once breast cancer becomes metastatic—meaning it has spread to distant parts of the body—outcomes become more challenging, though estrogen receptor-positive disease still generally has better survival compared to estrogen receptor-negative metastatic breast cancer. Metastatic breast cancer is considered treatable but not curable with current therapies. Patients with estrogen receptor-positive metastatic disease can often live for several years with good quality of life through sequential use of different hormone therapies and other treatments.

The presence of estrogen receptor mutations significantly impacts survival in the metastatic setting. Studies show that patients whose cancers harbor these mutations tend to have shorter progression-free survival and may have shorter overall survival compared to those without mutations. However, new treatments specifically designed to target mutant estrogen receptors are being developed and tested in clinical trials, offering hope for improved outcomes for this group of patients.^[4]^[6]

It’s important to remember that survival statistics are based on large groups of patients and represent averages. Individual outcomes can vary widely based on numerous factors including the specific characteristics of the cancer, the patient’s overall health, access to advanced treatments, and participation in clinical trials. Many patients with estrogen receptor-positive breast cancer, even in advanced stages, live longer than average statistics would predict, particularly as new and more effective treatments continue to be developed.

#1 Clinical Trials Search in Europe